Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|May 17, 2013
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extensionEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
The Journal of Rheumatology|November 17, 2014
Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohortGrace Yang, Vivian P Bykerk, Gilles Boire, et al.
Rheumatology and Therapy|May 24, 2021
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension StudyAlvin F Wells, Bochao Jia, Li Xie, et al.
The Journal of Rheumatology|March 17, 2006
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experienceLarry W Moreland, Michael E Weinblatt, Edward C Keystone, et al.
Arthritis and Rheumatism|March 31, 2007
Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohortDinesh Khanna, MyungShin Oh, Daniel E Furst, et al.
Rheumatology International|August 31, 2013
Factors associated with time to diagnosis in early rheumatoid arthritisCheryl Barnabe, Juan Xiong, Janet E Pope, et al.
The Journal of Rheumatology|April 17, 2012
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyMark C Genovese, Chenglong Han, Edward C Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Rheumatology and Therapy|November 1, 2024
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL StudyBoulos Haraoui, Majed Khraishi, Denis Choquette, et al.
The Journal of Rheumatology|January 30, 2010
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trialsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|May 17, 2013
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extensionEdward C Keystone, Mark C Genovese, Stephen Hall, et al.
The Journal of Rheumatology|November 17, 2014
Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohortGrace Yang, Vivian P Bykerk, Gilles Boire, et al.
Rheumatology and Therapy|May 24, 2021
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension StudyAlvin F Wells, Bochao Jia, Li Xie, et al.
The Journal of Rheumatology|March 17, 2006
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experienceLarry W Moreland, Michael E Weinblatt, Edward C Keystone, et al.
Arthritis and Rheumatism|March 31, 2007
Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohortDinesh Khanna, MyungShin Oh, Daniel E Furst, et al.
Rheumatology International|August 31, 2013
Factors associated with time to diagnosis in early rheumatoid arthritisCheryl Barnabe, Juan Xiong, Janet E Pope, et al.
The Journal of Rheumatology|April 17, 2012
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyMark C Genovese, Chenglong Han, Edward C Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Rheumatology and Therapy|November 1, 2024
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL StudyBoulos Haraoui, Majed Khraishi, Denis Choquette, et al.
The Journal of Rheumatology|January 30, 2010
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trialsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Pageof 16